Join us at 4pm BST on the 29th April for the fourth episode in our four-part series on Cancer Research, with Prof Dean Fennell, University of Leicester. In the period 7th April-29th April, Researcher Live will feature exclusive sessions on innovations and advancements in cancer research, spotlighting experts in the field. Sign up here to receive email updates about this series.
  • 7th April, 10am BST - Prof Ann Ager, Cardiff University: 'T cell homing in cancer immunotherapy: challenges and opportunities'


  • 21st April, 10am BST - Dr Luke Tattersall, University of Sheffield: ‘Preclinical bone cancer research’


  •  27th April, 4pm BST - Prof Chris Bakal, Institute of Cancer Research: ‘The shape of you: Using AI, bioengineering, and statistical cell biology to understand how changes in cell morphogenesis drives cancer’


  • 29th April, 4pm BST- Prof Dean Fennell, University of Leicester: ‘Mesothelioma. The evolving treatment landscape and future directions’


Mesothelioma is a lethal, rare cancer caused by asbestos. For the last two decades, progress has been slow in improving clinical outcomes due to a paucity of effective treatments. This has rapidly changed. This talk will summarise these advances, the challenges which remain and some future directions for development in the arena of precision medicine.
In this third sesseion, Prof Dean Fennell will discuss mesothelioma, research into improving treatments and future directions.


To speak at a Researcher Live session, please email kristine.lennie@researcher-app.com 


Follow the Researcher Live's 'Strides in Cancer Research' profile for updates on the series, by clicking here.

Date and Time
Friday, April 29, 2022 3:00 PM 03:00 pm - 04:00 pm GMT+0
Speakers Avatar Prof Dean Fennell, University of Leicester

After basic specialist training at UCL, Hammersmith, Brompton, Guy’s and St Thomas’ Hospitals in London, Prof Dean Fennell obtained membership of the Royal College of Physicians, followed by a PhD in Oncology as a MRC Clinical research fellow in UCL. He completed training in Medical Oncology at St Bartholomew’s Hospital and then undertook back-to-back Cancer Research UK (CRUK) Clinician Scientist Fellowships based at the CRUK Centre in Belfast. He was elected fellow of the Royal College of Physicians (London) in 2007. He also served two terms on the board of the European Organisation for Research and Treatment of Cancer (EORTC), led a translational research laboratory and international clinical trials portfolio focused on translating novel precision medicine strategies from the lab to the clinic.


He is the current president of the International Mesothelioma interest group, co-chairing the global meeting in the UK in 2016. He was also a planning committee member of the 2016 International  Association for the Study of Lung Cancer (IASLC) world lung cancer conference. He has written more than 100 publications in journals including Lancet, Lancet Oncology, Proceedings of the National Academy of Science, Nature Communications and Journal of the National Cancer Institute.

DOI: hnPC6jAzZ5UdrMbRrlEk_prepost_1

You might also like
Discover & Discuss Important Research

Keeping up-to-date with research can feel impossible, with papers being published faster than you'll ever be able to read them. That's where Researcher comes in: we're simplifying discovery and making important discussions happen. With over 19,000 sources, including peer-reviewed journals, preprints, blogs, universities, podcasts and Live events across 10 research areas, you'll never miss what's important to you. It's like social media, but better. Oh, and we should mention - it's free.

  • Download from Google Play
  • Download from App Store
  • Download from AppInChina

Researcher displays publicly available abstracts and doesn’t host any full article content. If the content is open access, we will direct clicks from the abstracts to the publisher website and display the PDF copy on our platform. Clicks to view the full text will be directed to the publisher website, where only users with subscriptions or access through their institution are able to view the full article.